Artelo to Present Expanded Clinical Data at Cannabinoid Summit
Patients in Artelo’s CAReS Phase 2 trial of ART27.13, a once-daily dual cannabinoid agonist for cancer-related anorexia, gained an...
MMI’s New Robotic Study Enrolls Its First Patient in U.S.
Up to 455 patients across two cohorts will be enrolled in a prospective, multi-center U.S. study evaluating the Symani...
Aprea Sets Phase 2 Dose for ATRN-119 Combination Therapy
Aprea set the monotherapy recommended Phase 2 dose for ATRN-119, its oral ATR inhibitor, at 1,100 mg once daily...
First Patient Enrolled for Prostate Cancer Trial in Japan
Curium’s global Phase 3 ECLIPSE trial of 177Lu-PSMA-I&T met its primary endpoint with statistically significant, clinically meaningful benefit in...
Eyepoint Begins Pivotal Phase 3 Trial for Duravyu™ in DME
Phase 2 signals for EyePoint’s vorolanib intravitreal insert include an approximately 88% reduction in treatment burden at six months...
Surging Lung Cancer ADC Market: FDA Trials & Opportunity
Global lung cancer ADCs have moved from niche to scale: the new Kuick Research analysis pegs 2024 revenue at...
OX40 Targeted Therapy Trials & Market Opportunity Insight 2026
Across OX40/OX40L programs, concrete signals are emerging: in asthma, an amlitelimab-responsive subgroup reported more than a 70% reduction in...
Promising Pancreatic Cancer Data from Cellectar Biosciences
In three pancreatic ductal adenocarcinoma xenograft models (PANC-1, MIA PaCa-2, and BxPC-3), Cellectar’s actinium-225 phospholipid ether conjugate CLR 225...
First Pharma to Restore Sense of Smell? Inside the FLAVOR Trial Quest to Treat Postviral Olfactory Loss
In this interview, I’m talking with Rick Geoffrion, Founder, President, and CEO of Cyrano Therapeutics, about FLAVOR, a Phase...
“Minutes, Not Days”: Site-Centric AI and Clinical Trial Experience
The coordinator stared at a 400-page EHR export, convinced the week was lost—until an AI pre-screen flagged 23 likely-eligible...